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Although considerable research concerning the efficacy of analgesics in sport exists, there is a paucity 
of data concerning effects of acute acetaminophen (ACT) ingestion on sprint interval running exercise. 
This investigation concerned the effect of acute ACT ingestion on eight 30 s maximal treadmill sprints on a 
non-motorized treadmill, interspersed with two-minute rests in males (N=8, age 26±3 years, body height 174±7 
cm, body mass 71±8 kg) in a placebo-controlled, randomized crossover design. A time x condition repeated 
measures analysis of variance (ANOVA) determined ACT ingestion did not influence mean power output, 
peak power output, peak vertical ground reaction force, peak oxygen uptake, or total distance completed 
(p>.05). Perceived pain was reduced by 8-15% during the final three sprints following ACT ingestion (p<.05). 
Data presented here suggest ACT may reduce exercise-induced pain during the latter stages of sprint interval 
treadmill running, without influencing performance. 
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Introduction
Acetaminophen (ACT) is a commonly used 
over-the-counter analgesic to reduce musculoskel-
etal pain in sub-elite athletes (Garcin, et al., 2005; 
Lily, 2010; McDonald & Molloy, 2012). Although 
the primary mechanism of action for ACT is poorly 
understood, it exhibits both analgesic and anti-
pyretic properties (Blough & Wu, 2011). ACT is 
thought to act similarly to ibuprofen as a cyclooxy-
genase inhibitor without influencing inflammation 
or oedema, whilst modulating afferent and efferent 
pain pathways (Bonnefont, Alloui, Chapuy, Clottes, 
& Eschalie, 2003; Boutaud, Aronoff, Richardson, 
Marnett, & Oates, 2002; Pickering, et al., 2006).
Although limited research exists regarding the 
role of ACT in exercise performance, acute ACT 
ingestion has been reported to improve time to 
exhaustion during running and cycling performed 
in the heat (Burtscher, et al., 2013; Mauger, et al., 
2014). These studies provided initial evidence that 
ACT ingestion may be used as an ergogenic aid due 
to its antipyretic properties. Foster and colleagues 
(2014) explored the analgesic influence of ACT 
during sprint interval cycling (Foster, Taylor, 
Chrismas, Watkins, & Mauger, 2014). Participants 
completed eight 30 s Wingate Anaerobic Tests, 30 
minutes after ingesting 1.5 g of ACT or a placebo 
(PLA). The authors indicated a significant improve-
ment in mean power output in the ACT condition 
compared to PLA. This was attributed to increased 
mean power output during the final three sprints, 
accompanied by significantly slower power dimi-
nution. No significant differences were observed 
for pain perception, peak power output, or heart 
rate between ACT and PLA conditions. The authors 
suggested ACT permitted participants to tolerate 
increased muscular pain associated with this type 
of exercise. Therefore, these authors suggested 
untrained cyclists may rely on afferent feedback to 
calculate an appropriate pacing strategy.
Stocchero et al. (2014) explored metabolic 
differences between intense running and cycling 
exercise and observed serum creatine kinase (CK) 
was greater after intense running than after intense 
cycling. Moreover, Nieman et al. (2014) observed 
that after three days of intensified training, runners 
experienced a greater relative increase in pro-
inflammatory cytokines than did cyclists. In addi-
tion, Kolkhorst, Londeree, and Thomas (1994) 
observed post-running muscular soreness was 
greater and lasted longer than following cycling. 
This intimates potential for a greater muscle damage 
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following running compared to cycling, and there-
fore the possibility that ACT may improve running 
performance to a greater extent than cycling perfor-
mance requires exploration. 
Although considerable research exists concern-
ing the efficacy of analgesics in sport, there is a 
paucity of data concerning the effect of acute 
ACT ingestion on sprint interval running perfor-
mance. Consequently, the purpose of this study 
was to investigate whether an acute dose of ACT 




Following an a priori power calculation, eight 
recreationally active male participants (N=8, age 
26±3 years, body height 174±7 cm, body mass 
71±8 kg), who participated in regular exercise (4±2 
sessions·wk-1), were recruited for the present study. 
Prior to study commencement, participants were 
required to provide written informed consent and 
complete a Physical Activity Readiness Question-
naire (PAR-Q). Prior to experimental trials, partici-
pants were given a verbal and written explanation 
of the protocol and the opportunity to familiarize 
themselves with the laboratory and experimental 
conditions on a calibrated WOODWAY®Force 
3.0 treadmill. Ethical approval was granted by the 
London Metropolitan University research ethics 
review panel.
Experimental procedures
Following three initial familiarization sessions, 
participants reported to the laboratory on two sepa-
rate occasions (separated by a minimum of 48 h) and 
completed testing at the same time of day to amelio-
rate the influence of diurnal variation (Hayes, Bick-
erstaff, & Baker, 2010). Upon arrival at the labora-
tory, participants orally ingested either 1.5 g ACT 
or placebo (PLA) taste-matched solution adminis-
tered in a randomized, double-blinded, crossover 
design. Thirty minutes post-ingestion, participants 
completed a standardized 5 min warm-up involving 
walking at a moderate pace interspersed with two 
10 to 15 second all-out sprints. A recovery period 
of 5 minutes was allowed between the warm-up 
and the test. Participants performed eight 30-second 
maximal sprints, separated by two-minute active 
rests to allow time for substantial recovery, and to 
prevent substantial lactate clearance, in order to 
facilitate an increase in pain and fatigue (Mendez-
Villanueva, Hamer, & Bishop, 2007). For each 
stage, participants were provided with a 5 s count-
down and verbal encouragement throughout. Partic-
ipants did not receive any feedback (visual or verbal) 
concerning sprint performance (distance covered, 
time remaining, power output). All sprints were 
performed on a non-motorized treadmill as previ-
ously described (Delextrat, Baliqi, & Clarke, 2013). 
Subjects were equipped with a harness around their 
waist, connected by a non-elastic tether to a hori-
zontal load cell attached to the vertical strut of the 
treadmill which was locked during sprinting. For 
each participant, the gauge was adjusted to ensure 
the tether was horizontal during sprinting. This 
device was used to measure horizontal force (N). 
Treadmill speed was monitored by two optical speed 
photomicrosensors mounted on the rear shaft of the 
treadmill belt, while vertical force (N) was recorded 
by four individual vertical load cells mounted onto 
the underside of the belt. Power (W) was computed 
from instantaneous force and speed data. Data were 
collected at a sampling rate of 75 Hz by the XPV7 
PCB interface. Peak power output (W), mean power 
output (W), peak vertical ground reaction (GRFV 
[kg]) and distance completed (m) were collected 
and calculated at 200 Hz sample rate throughout 
the test using the WOODWAY®Force 3.0 software 
package. Intra-class correlations have been previ-
ously reported as r=.89, .94, and .97 for peak power 
output, mean power output, and distance covered, 
respectively, during 30 s sprints on a non-motorized 
treadmill (Gonzalez, et al., 2013).
Oxygen uptake
Oxygen uptake (ml·kg·min-1) was determined 
by open circuit spirometry using Quark PFT 
(COSMED, Italy). Expiratory airflow was achieved 
using a volume transducer connected to an oxygen 
analyser. Prior each test, the Quark PFT was cali-
brated according to the manufacturers’ guidelines. 
After a 60 minute warm-up period, the carbon 
dioxide and oxygen sensors were calibrated against 
room air in addition to a reference gas of a known 
composition (5% carbon dioxide, 15% oxygen, and 
80% nitrogen) with volume calibrated using a 3 L 
pump. Oxygen uptake (VO2) carbon dioxide uptake 
(VCO2) respiratory exchange ratio, and minute 
ventilation were displayed continuously. Breath-
by-breath data were sampled and transferred to a 
PC for real-time display. The recorded data were 
saved to the internal database until analysis. The 
coefficient of variation for VO2 determination using 
online systems has previously been determined as 
<3% (Foss & Hallen, 2005; Hayes, et al., 2015).
Pain scale
Participants were asked to provide pain per-
ception ratings following each sprint (Cook, 
O’Connor, Eubanks, Smith, & Lee, 2007). A ten-
point scale accompanied with verbal, written and 
visual descriptions was used. This was chosen given 
high intra-class correlations (r=.88-.98) suggest 
this scale is a reliable measure of pain perception 
during exercise (Cook, et al., 2007). Standardized 
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verbal instruction of the correct use of the scale 
was provided prior to each experimental procedure. 
Statistical analysis
Data were analyzed using IBM SPSS statistics 
version 21.0 (IBM Corp, NY, USA). Parametric 
assumptions were checked using numerical methods: 
checking studentized residual, Shapiro-Wilk test 
and Mauchly’s Test of sphericity. Following confi r-
mation of parametricity, mean differences in mean 
power output, peak power output, GRFv, peak VO2, 
distance completed, and perceived pain between the 
two experimental conditions (ACT and PLA) were 
assessed using a two-way (condition x sprint) anal-
ysis of variance (ANOVA) with repeated measures 
and posteriori Sidak. The difference in distance 
completed over the eight bouts was analysed using 
a paired samples t-test. Alpha was set a priori at 
p<.05 and 95% confi dence intervals (CI) and effect 
sizes (ES) are displayed where appropriate. Data are 
presented as mean±standard deviation (SD).
Results
No main effect of condition (p=.83; ES=.01), 
or interaction between condition and bout (p=.22; 
ES=.17) was observed for peak power output 
between ACT (1008±418 W, 95% CI=909-1108 W)
and PLA (983±374 W, 95% CI=894-1072 W) 
conditions (Figure 1:A). No signifi cant main effect 
(p=.64; ES=.03), or interaction effect (p=.21; 
ES=.17) was observed for mean power output 
between ACT (320±119 W, 95% CI=292-3486 
W) and PLA (323±119 W, 95% CI=295-351 W) 
conditions (Figure 1:B). No signifi cant main effect 
(p=.31; ES=.15) was found for pain perception 
between ACT (5.97±2.35, 95% CI=5.41-6.53) and 
PLA (6.24±2.78, 95% CI=5.58-6.91) conditions. A 
signifi cant interaction effect existed between condi-
tion and sprint number (p<.001; ES=.61). Posteriori 
Sidak adjustment revealed that pain perception was 
signifi cantly reduced during sprint six (8.6±1.4 
compared to 7.4±1.4), seven (8.9±1.4 compared to 
7.7±1.5), and eight (9.3±0.9 compared to 8.6±1.1) 
during the ACT condition compared to the PLA 
condition (Figure 1:C).
No signifi cant main effect (p=.42; ES=.10) was 
observed for peak GRFv between ACT (178±27 
kg, 95% CI=172-185 kg) and PLA (185±60 kg, 
95% CI=171-200 kg) conditions. No effect of condi-
tion (p=.47; ES=.08) was observed for peak VO2 
between ACT (48±7 ml·kg·min-1, 95% CI=46-50 
ml·kg·min-1) and PLA (49±8 ml·kg·min-1, 95% 
CI=47-51 ml·kg·min-1) conditions (Figure 1:D). 
Paired-samples t-test revealed no signifi cant differ-
ence in distance completed between ACT (664±109 
m, 95% CI=580-748 m) and PLA (657±111 m, 95% 
CI=572-742 m) conditions (p=.31). 
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Figure. 1 A: Peak power output during 8 x 30 s treadmill sprints. B: Mean power output 
during 8 x 30 s treadmill sprints. C: Peak oxygen uptake observed during each 30 s treadmill 
sprint. D: Perceived pain after 8 x 30 s treadmill sprints. Data are presented as mean±standard 
error for clarity. Acetaminophen: solid line. Placebo: dashed line. *denotes a significant 
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Figure. 1 A: Peak power output during 8 x 30 s treadmill sprints. B: Mean power output 
during 8 x 30 s treadmill sprints. C: Peak oxygen uptake observed during each 30 s treadmill 
sprint. D: Perceived pain after 8 x 30 s treadmill sprints. Data are presented as mean±standard 
error for clarity. Acetaminophen: solid line. Placebo: dashed line. *denotes a significant 
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Fi u e 1. A: Peak power output during 8 x 30 s tre dmill 
sprints. B: Mean power output during 8 x 30 s treadmill 
sprints. C: Peak oxygen uptake observed during each 30 s 
treadmill sprint. D: Perceived pain afte  8 x 30 treadmill
sprints. Data are presented as mean±standard error for 
clarity. Acetaminophen: solid line. Placebo: dashed line. 
*denotes a significant difference between groups (p<.05).
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Discussion
The main finding of the present study was 
that ACT ingestion did not improve sprint internal 
treadmill running performance. However, pain 
perception was reduced during sprint six, seven, 
and eight using the ACT condition compared to the 
PLA condition. This suggests ACT may be used to 
reduce exercise-induced pain in the latter stages of 
sprint interval training.
Results of the present study differ from those 
concerning cycling performance, where a signifi-
cant change was observed for peak power output 
and mean power output accompanied by unaltered 
pain perception (Foster, et al., 2014). These findings 
in combination with the present investigation indi-
cate ACT ingestion may be used to either improve 
performance, or minimise pain perception during 
repeated sprint exercise at a given exercise intensity. 
Findings from the present investigation indicate that 
exercise-induced pain did not significantly influ-
ence sprint interval performance, as pain perception 
decreased without significant alteration in perfor-
mance parameters. A possible explanation for this 
is that muscle fatigue does not only occur in the 
working muscle, but is a conscious awareness of 
physical activity in which exercise-induced neuro-
muscular pain is one factor amongst a multitude 
of factors that influence central drive (Bundle & 
Weyand, 2012; Noakes, 2012; St Clair Gibson, et 
al., 2003).
Amann, Proctor, Sebranek, Pegelow, and 
Dempsey (2009) previously demonstrated that 
complete removal of pain with an opioid analgesic 
enabled participants to experience higher toler-
ance to peripheral neuromuscular fatigue during 
initial stages of exercise, but at a cost of increased 
diminution in mean power output during the final 
stages, resulting in no net increase in performance. 
This occurred as a result of participants adopting a 
more aggressive approach to their pacing strategy, 
resulting in greater levels of end-exercise periph-
eral neuromuscular fatigue. Therefore, it appears 
a degree of afferent neuromuscular feedback is 
required to maintain an appropriate pacing strategy 
and not induce premature fatigue (Amann, et al., 
2009).
That we report no significant differences 
between the ACT and PLA conditions for peak 
GRFv is likely due to participants exceeding veloci-
ties of 6 m∙s-1 for both ACT and PLA conditions. 
During velocities greater than 6 m∙s-1, peak GRFv 
remains relatively constant on a non-motorized 
treadmill despite any increase in running velocity 
(Brughelli, Cronin, & Chouachi, 2010) and there-
fore our findings are in line with previous studies 
(Brughelli, et al., 2010).
That improved power profiles were observed 
following ACT ingestion by previous investiga-
tions (Foster, et al., 2014) but not in the present 
study is puzzling. However, a possible explana-
tion may be that sprint interval cycling results in 
greater peripheral neuromuscular fatigue than does 
repeated sprint exercise running (Rampinini, et al., 
2014). Moreover, Rampinini and colleagues (2014) 
reported rating of perceived exertion (RPE) to be 
higher during repeated sprint cycling compared to 
repeated sprint running. We therefore propose that 
ACT may have a greater ergogenic potential during 
activities where peripheral neuromuscular fatigue 
(and therefore RPE) is higher such as cycling and 
resistance exercise. However, further research is 
required to test this hypothesis.
In conclusion, the present study was the first 
to investigate the effects of 1.5 g ACT ingestion on 
sprint interval treadmill running. Results presented 
here suggest that sprint interval treadmill running 
performance was not influenced by ACT ingestion; 
however, pain perception was decreased during the 
final stages of exercise. Future research may wish to 
investigate events where peripheral neuromuscular 
fatigue is high as ACT may have more potential as 
an ergogenic aid.
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